406725-56-2

Upstream product

• 2393-17-1 3-(4-aminophenyl)propionic acid 
• 98-88-4 benzoyl chloride 
• 35418-07-6 methyl 3-(4-aminophenyl)propionate 
• 54405-42-4 methyl 3-(4-nitrophenyl)propanoate 
• 16642-79-8 3-(4-nitrophenyl)propionic acid 
• 501-52-0 3-Phenylpropionic acid 
• 953-26-4 ethyl 4-nitrocinnamate 
• 7116-44-1 ethyl 4-aminohydrocinnamate 
• 116557-37-0 4-benzamino-trans-cinnamic acid 

Downstream Products

• 408351-31-5 N-[4-(2-Hydroxycarbamoyl-ethyl)-phenyl]-benzamide 

Relevant academic research and scientific papers

Design, synthesis and structure–activity relationship studies of novel free fatty acid receptor 1 agonists bearing amide linker

The free fatty acid receptor 1 (FFA1/GPR40) has attracted extensive attention as a novel antidiabetic target. Aiming to explore the chemical space of FFA1 agonists, a new series of lead compounds with amide linker were designed and synthesized by combining the scaffolds of NIH screened lead compound 1 and GW9508. Among them, the optimal lead compound 17 exhibited a considerable agonistic activity (45.78%) compared to the NIH screened compound 1 (15.32%). During OGTT in normal mice, the compound 17 revealed a significant glucose-lowering effect (?23.7%) at the dose of 50?mg/kg, proximity to the hypoglycemic effect (?27.8%) of Metformin (200?mg/kg). In addition, the compound 17 (100?mg/kg) also exhibited a significant improvement in glucose tolerance with a 29.1% reduction of glucose AUC0–2?h in type 2 diabetic mice. All of these results indicated that compound 17 was considered to be a promising lead structure suitable for further optimization.

Carbamic acid compounds comprising an amide linkage as hdac inhibitors

This invention pertains to certain active carbamic acid compounds which inhibit HDAC activity and which have the formula (1) wherein: A is an aryl group; Q1 is an aryl leader group having a backbone of at least 2 carbon atoms; J is an amide linkage selected from: —NR1C(═O)—and —C(═O)NR1—; R1 is an amido substituent; and, Q2 is an acid leader group; and pharmaceutically acceptable salts, solvates, amides, esters, ethers, chemically protected forms, and prodrugs thereof. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit HDAC, and, e.g., to inhibit proliferative conditions, such as cancer and psoriasis.